Madrigal Pharmaceuticals, Inc. (MDGL)Healthcare | Biotechnology | West Conshohocken, United States | NasdaqGS
531.00 USD
-5.70
(-1.062%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:39 a.m. EDT
The long-term rating reflects a high-conviction growth story backed by exceptional revenue expansion and a fortress-like balance sheet, despite the company still operating at a loss. The nine-year price trajectory is a testament to this quality, delivering a massive cumulative gain without a recent multi-year decline. The short-term rating acknowledges the upward trend above key moving averages, yet the high beta and mixed options flow temper full conviction. While analysts maintain a strong buy stance, the high valuation and ongoing cash burn require careful monitoring of clinical milestones to sustain the premium. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.031022 |
| AutoETS | 0.031022 |
| MSTL | 0.034719 |
| AutoTheta | 0.074498 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 2.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.085 |
| Excess Kurtosis | 0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 63.908 |
| Revenue per Share | 49.953 |
| Market Cap | 12,242,555,904 |
| Forward P/E | 42.89 |
| Beta | -1.06 |
| Profit Margins | -27.32% |
| Website | https://www.madrigalpharma.com |
As of July 11, 2026, 3:39 a.m. EDT: Speculators are positioning for volatility with heavy out-of-the-money call interest near term, suggesting a bullish bias, though significant put volume indicates hedging against downside risk. Longer-dated calls show more in-the-money positioning, hinting at sustained upside expectations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.70662725 |
| Address1 | Four Tower Bridge |
| Address2 | 200 Barr Harbor Drive Suite 200 |
| All Time High | 615.0 |
| All Time Low | 5.25 |
| Ask | 531.85 |
| Ask Size | 1 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 334,460 |
| Average Daily Volume3 Month | 327,785 |
| Average Volume | 327,785 |
| Average Volume10Days | 334,460 |
| Beta | -1.056 |
| Bid | 526.22 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 23.585 |
| City | West Conshohocken |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 531.0 |
| Current Ratio | 3.495 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 539.065 |
| Day Low | 526.14 |
| Debt To Equity | 63.908 |
| Display Name | Madrigal Pharmaceuticals |
| Dividend Date | 1,469,404,800 |
| Earnings Call Timestamp End | 1,778,068,800 |
| Earnings Call Timestamp Start | 1,778,068,800 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -311,996,000 |
| Ebitda Margins | -0.2755 |
| Enterprise To Ebitda | -37.748 |
| Enterprise To Revenue | 10.399 |
| Enterprise Value | 11,777,094,656 |
| Eps Current Year | -6.52333 |
| Eps Forward | 12.38 |
| Eps Trailing Twelve Months | -13.34 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 511.7298 |
| Fifty Day Average Change | 19.270203 |
| Fifty Day Average Change Percent | 0.03765699 |
| Fifty Two Week Change Percent | 70.66273 |
| Fifty Two Week High | 615.0 |
| Fifty Two Week High Change | -84.0 |
| Fifty Two Week High Change Percent | -0.13658537 |
| Fifty Two Week Low | 286.44 |
| Fifty Two Week Low Change | 244.56 |
| Fifty Two Week Low Change Percent | 0.85379136 |
| Fifty Two Week Range | 286.44 - 615.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,170,772,200,000 |
| Float Shares | 13,995,016 |
| Forward Eps | 12.38 |
| Forward P E | 42.89176 |
| Free Cashflow | -156,403,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 915 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.9307 |
| Gross Profits | 1,054,008,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.056799997 |
| Held Percent Institutions | 1.0699099 |
| Implied Shares Outstanding | 23,055,659 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.syntapharma.com/phoenix.zhtml?c=147988&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,469,404,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. |
| Long Name | Madrigal Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 12,242,555,904 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_144939852 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -309,436,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,252,699,418 |
| Number Of Analyst Opinions | 14 |
| Open | 534.05 |
| Operating Cashflow | -268,096,992 |
| Operating Margins | -0.29782 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 267 824 2827 |
| Previous Close | 536.7 |
| Price Eps Current Year | -81.40014 |
| Price Hint | 2 |
| Price To Book | 22.51431 |
| Price To Sales Trailing12 Months | 10.8103 |
| Profit Margins | -0.27324 |
| Quick Ratio | 2.957 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -5.70001 |
| Regular Market Change Percent | -1.06205 |
| Regular Market Day High | 539.065 |
| Regular Market Day Low | 526.14 |
| Regular Market Day Range | 526.14 - 539.065 |
| Regular Market Open | 534.05 |
| Regular Market Previous Close | 536.7 |
| Regular Market Price | 531.0 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 287,877 |
| Return On Assets | -0.17621 |
| Return On Equity | -0.49348 |
| Revenue Growth | 1.268 |
| Revenue Per Share | 49.953 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 23,055,659 |
| Shares Percent Shares Out | 0.153 |
| Shares Short | 3,526,539 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,823,127 |
| Short Name | Madrigal Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.17989999 |
| Short Ratio | 8.54 |
| Source Interval | 15 |
| State | PA |
| Symbol | MDGL |
| Target High Price | 964.0 |
| Target Low Price | 542.0 |
| Target Mean Price | 678.7143 |
| Target Median Price | 649.5 |
| Total Cash | 812,771,008 |
| Total Cash Per Share | 35.253 |
| Total Debt | 347,311,008 |
| Total Revenue | 1,132,489,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -13.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 500.38364 |
| Two Hundred Day Average Change | 30.616364 |
| Two Hundred Day Average Change Percent | 0.06118578 |
| Type Disp | Equity |
| Volume | 287,877 |
| Website | https://www.madrigalpharma.com |
| Zip | 19,428 |